✨ Free AI Report
Seres Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Seres Therapeutics, Inc.
Company Research

Seres Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Seres Therapeutics is a late-clinical-stage biotechnology company working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. The company led the successful devel...

Analyst-debate audio for Seres Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Seres Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Weak

Cyborg Score thesis

Highly speculative pre-revenue clinical biotech facing existential cash constraints, pivoting strategy while awaiting Q2 2026...

Read the full analyst-debate transcript →
Industry Biotechnology - Live Biotherapeutics / Microbiome Therapeutics
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Seres Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Seres Therapeutics, Inc. Overview

Pro stress-test →

Seres Therapeutics is a late-clinical-stage biotechnology company working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. The company led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome biotherapeutic, which was sold to Nestlé Health Science in September 2024.

Strategic Profile

Pro stress-test →

Seres has implemented a corporate strategy to advance its live biotherapeutic programs in inflammatory and immune diseases, with a focus on inflammatory bowel disease and immune checkpoint-related enterocolitis. The company has reduced workforce by approximately 30% to extend cash runway through Q3 2026, pausing additional investment in the SER-155 Phase 2 transplant program while prioritizing early-stage inflammatory disease programs.

Competitive Landscape

Pro stress-test →

Seres competes in the live biotherapeutics and microbiome therapeutics space with competitors including Fate Therapeutics, Vir Biotechnology, and Altimmune. The company's differentiation comes from its Breakthrough Therapy-designated programs and successful VOWST proof-of-concept, though it faces challenges from larger biotechs with deeper pipelines and superior capitalization.

Industry Context

Seres Therapeutics, Inc. operates in Biotechnology - Live Biotherapeutics / Microbiome Therapeutics.

Key facts

Founded: 2010 · Headquarters: Cambridge, Massachusetts, US · Market cap: $71.78M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Seres Therapeutics, Inc..

  • Richard N. Kender was appointed as Executive Chair and Interim CEO as of March 2, 2026, bringing over 35 years of biopharma executive experience including a senior role at Merck & Co.
  • SER-155 investigator-sponsored trial in immune checkpoint-related enterocolitis is fully enrolled with initial data expected in early Q2 2026, representing a near-term binary catalyst.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Richard N. Kender appointed Executive Chair and Interim CEO; co-CEOs transitioned to CLO/CFO roles
  • February 202630% workforce reduction implemented to extend cash runway through Q3 2026; SER-155 Phase 2 allo-HSCT program paused
  • +2 moreTrack every material event for Seres Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Seres Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Fate TherapeuticsCell therapy and immunotherapy company developing off-the-shelf cellular therapies→Vir BiotechnologyAntiviral and immunotherapy company with infectious disease focus→AltimmuneImmunology company developing intranasal vaccines and therapeutics→

Compare Seres Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Seres Therapeutics, Inc. operates in Biotechnology - Live Biotherapeutics / Microbiome Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Live Biotherapeutics / Microbiome Therapeutics research →
NEW · MCP server

Ask your AI assistant about Seres Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Seres Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Seres Therapeutics, Inc. do this quarter?”
“Is Seres Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Seres Therapeutics, Inc. do?+
Seres Therapeutics is a late-clinical-stage biotechnology company working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome. The company led the successful devel...
What is Seres Therapeutics, Inc.'s Cyborg Score?+
Seres Therapeutics, Inc. has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Seres Therapeutics, Inc.'s main competitors?+
Named competitors include Fate Therapeutics, Vir Biotechnology, Altimmune. The full competitive landscape is in the AskCyborg report.
How can I get the full Seres Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Seres Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Seres Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Live Biotherapeutics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4Azitra, Inc.7Altimmune, Inc.